At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 5, 2026 at 13:27 ET
FMR LLC (Fidelity) filed an amended Schedule 13G reporting a 6.1% passive stake in Travere Therapeutics as of September 30, 2026, up from 5.0% in the prior filing. The increase follows strong Q3 FILSPARI sales of $200.2M (up 120% YoY) reported on November 2, 2026. This is a routine passive stake update with no change in investment intent.
- FMR LLC reported beneficial ownership of 5,707,883 shares of Travere Therapeutics common stock as of September 30, 2026
- The stake represents 6.1% of shares outstanding
- This is an amendment to a Schedule 13G, indicating passive investment intent
- The prior FMR LLC filing (August 6, 2026) reported a 5.0% stake
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access